drugset

drugset / Trial / NCT00586495

Long-term Extension From RCC Phase II (11515)

NCT00586495 ↗

Phase 2 Completed 95 enrolled Bayer

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Extension to study 11515 (NCT00661375) which was a multicenter study of sorafenib in patients with renal cell carcinoma (RCC).

Timeline

Start: 2005-12
Primary completion: 2008-06
Completion: 2008-07

Publications

Results Naito S, Tsukamoto T, Murai M, Fukino K, Akaza H. Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma. BJU Int. 2011 Dec;108(11):1813-9. doi: 10.1111/j.1464-410X.2011.10281.x. Epub 2011 Apr 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sorafenib	Small molecule	400 mg	Oral

Indications